{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:43:46Z","timestamp":1761093826366,"version":"build-2065373602"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2846,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:p>A 9\u2010year\u2010old girl was hospitalized with prolonged somnolence that began 3.5 hours after a single 15\u2010mg dose of aripiprazole. After extensive workup, physical examinations were unremarkable, and all laboratory test results were within normal limits. The patient's extreme somnolence was attributed to aripiprazole, a new atypical antipsychotic prescribed for oppositional defiant disorder. In clinical trials, somnolence has been reported with a frequency of approximately 11%. However, the somnolence experienced by this child was severe, requiring 24\u2010hour hospitalization for observation. Although a recent dose\u2010finding study in 22 pediatric patients (\u2265 6 yrs old) described weight\u2010based dosages that were safe and well tolerated, dosing of aripiprazole in children has not been well established. Further studies are needed to identify optimal dosing of aripiprazole in pediatric patients.<\/jats:p>","DOI":"10.1592\/phco.24.5.522.33352","type":"journal-article","created":{"date-parts":[[2004,5,25]],"date-time":"2004-05-25T04:52:13Z","timestamp":1085460733000},"page":"522-525","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Excessive Somnolence from Aripiprazole in a Child"],"prefix":"10.1002","volume":"24","author":[{"given":"Jennifer D.","family":"Davenport","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle W.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia L.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C297"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1201"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2003.tb11397.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035458"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)00050-1"},{"key":"e_1_2_1_7_2","unstructured":"Bristol\u2010Myers Squibb.Abilify (aripiprazole) package insert. Princeton NJ;2003."},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-6163.2002.tb01566.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0903"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.681"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01532-7"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0910"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200205000-00011"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200205000-00008"},{"key":"e_1_2_1_15_2","first-page":"P5","article-title":"Pharmacokinetics, tolerability and safety of aripiprazole in children and adolescents with conduct disorder [abstr]","volume":"71","author":"Blumer JL","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_16_2","unstructured":"FindlingR. BlumerJ. KauffmanR. et al.Aripiprazole in pediatric conduct disorder: a pilot study [abstr]. In:Proceedings of the 16th congress of the European College of Neuropsychopharmacology Prague Czech Republic September 20\u201324 2003. Available fromhttp:ex2.excerptamedica.com03ecnp."},{"volume-title":"Diagnostic and statistical manual of mental disorders, 4th ed. (DSM\u2010IV)","year":"1994","author":"American Psychiatric Association.","key":"e_1_2_1_17_2"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199305000-00013"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.24.5.522.33352","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.24.5.522.33352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:16:58Z","timestamp":1761052618000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.24.5.522.33352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1592\/phco.24.5.522.33352"],"URL":"https:\/\/doi.org\/10.1592\/phco.24.5.522.33352","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}